Company intelligence / Profile preview

Autoimmunity BioSolutions

Houston, Texas, United States

Ownership: Private
Development stage: Other

Overview

ABS is developing first-in-class, highly specific monoclonal antibodies and antisense oligonucleotides that target the soluble interleukin-7 receptor (sIL7R), aiming to restore immune homeostasis in genetically defined subpopulations with autoimmune diseases resistant to current therapies. Clinical results have not yet been reported as the programs are preclinical, but the approach is supported by strong genetic and biochemical rationale.[1][3][5][14]

Therapeutic areas: ImmunologyNeurology
Modalities: Monoclonal antibodyAntisense oligonucleotide
Industry: Biotech

Beyond the preview

Go deeper on Autoimmunity BioSolutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autoimmunity BioSolutions.

Explore the full profile